Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Caryn Chasanov

Nurse Practitioner, Family Lewes, DE Nurse Practitioner

NPI 1992021687 CMS profile 10622926

34381 Carpenters Way, Lewes, DE 19958

Open in the dashboard

General payments

$12,179

458 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caryn Chasanov of Lewes, DE is reported in the CMS Open Payments database as having received $12,179 across 458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,739 130
2024 General $2,534 89
2023 General $2,906 114
2022 General $2,183 87
2021 General $818 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caryn Chasanov
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Caryn Chasanov were reported at $3,739. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Caryn Chasanov Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $818 $124 $35–$379 $132
2022 $2,183 $141 $44–$430 $149
2023 $2,906 $154 $49–$476 $160
2024 $2,534 $165 $51–$504 $164
2025 $3,739 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,076 73 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $766 23 payments
  3. GlaxoSmithKline, LLC. $734 35 payments
  4. Genzyme Corporation $628 29 payments
  5. Actelion Pharmaceuticals US, Inc. $535 15 payments
  6. Harmony Biosciences LLC $436 13 payments
  7. Amgen Inc. $436 20 payments
  8. Inspire Medical Systems, Inc. $414 6 payments
  9. Novo Nordisk Inc $410 19 payments
  10. Insmed, Inc. $392 11 payments
  11. Other $5,352 214 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,630 452 payments
  2. Education $280 3 payments
  3. Travel and Lodging $269 3 payments
Products named General payments · program years 2021–2025
  1. FASENRA $877 29 payments
  2. DUPIXENT $728 30 payments
  3. BREZTRI $618 16 payments
  4. TEZSPIRE $539 18 payments
  5. TRELEGY ELLIPTA $450 21 payments
  6. OPSUMIT $436 11 payments
  7. INSPIRE $414 6 payments
  8. AIRSUPRA $395 15 payments
  9. UPTRAVI $393 9 payments
  10. Arikayce $392 11 payments
  11. Other $8,704 359 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

2,669

Median for Nurse Practitioner: 389

Drug cost

$1,362,014

Median for Nurse Practitioner: $21,885

Branded share of claims

52.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 242 $306,789
Opsumit Macitentan Brand 15 $219,684
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 114 $146,749
Ofev Nintedanib Esylate Brand 12 $140,827
Breo Ellipta Fluticasone/Vilanterol Brand 130 $83,312
Fasenra Pen Benralizumab Brand 11 $70,454
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 67 $63,382
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 55 $57,526
Spiriva Respimat Tiotropium Bromide Brand 46 $35,286
Symbicort Budesonide/Formoterol Fumarate Brand 78 $26,605

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$59,739

Of which drugs: $14,114

Medicare patients

533

Average age 75

Services billed

1,351

271 women, 262 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 55%
Diabetes 34%
COPD 34%
Atrial fibrillation 31%
Chronic kidney disease 23%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $266
$266 12 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $107
  • Lilly USA, LLC $26
$133 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $124
$124 114 —
DUPIXENT
  • GENZYME CORPORATION $118
$118 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $53
  • Genentech USA, Inc. $53
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record